DK3024474T3 - Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist - Google Patents
Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist Download PDFInfo
- Publication number
- DK3024474T3 DK3024474T3 DK14748451.3T DK14748451T DK3024474T3 DK 3024474 T3 DK3024474 T3 DK 3024474T3 DK 14748451 T DK14748451 T DK 14748451T DK 3024474 T3 DK3024474 T3 DK 3024474T3
- Authority
- DK
- Denmark
- Prior art keywords
- adrenor
- desmopressine
- beta
- combination
- receptor agonist
- Prior art date
Links
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857431P | 2013-07-23 | 2013-07-23 | |
| PCT/US2014/047899 WO2015013454A1 (en) | 2013-07-23 | 2014-07-23 | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3024474T3 true DK3024474T3 (da) | 2022-03-28 |
Family
ID=51299056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14748451.3T DK3024474T3 (da) | 2013-07-23 | 2014-07-23 | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9814753B2 (da) |
| EP (1) | EP3024474B1 (da) |
| JP (2) | JP2016525548A (da) |
| KR (3) | KR20240015735A (da) |
| CN (1) | CN105579057A (da) |
| AU (1) | AU2014293141A1 (da) |
| CA (1) | CA2919198A1 (da) |
| DK (1) | DK3024474T3 (da) |
| ES (1) | ES2910361T3 (da) |
| MX (1) | MX2016001030A (da) |
| WO (1) | WO2015013454A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| PL3679941T3 (pl) | 2009-06-18 | 2023-04-17 | Serenity Pharmaceuticals Llc | Bezpieczne podawanie desmopresyny |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| JP2016525147A (ja) | 2013-07-23 | 2016-08-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物 |
| MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| ES2923438T3 (es) | 2014-11-20 | 2022-09-27 | Serenity Pharmaceuticals Llc | Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico |
| KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
| WO2017210700A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| KR101877834B1 (ko) * | 2017-04-27 | 2018-07-12 | 주식회사 다산제약 | 미라베그론의 신규한 염 및 이의 제조방법 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| IL101243A (en) | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| JP4754067B2 (ja) | 1997-12-02 | 2011-08-24 | アルキメデス ディヴェロプメント リミテッド | 鼻孔投与用組成物 |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| EP1412017B1 (en) | 2000-11-30 | 2016-04-13 | Valeritas, Inc. | Fluid delivery and measurement systems and methods |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| MXPA05004925A (es) * | 2002-11-07 | 2005-08-18 | Yamanouchi Pharma Co Ltd | Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo. |
| EP2322195A2 (en) * | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
| CN101829319A (zh) | 2003-12-08 | 2010-09-15 | Cpex药品公司 | 用于胰岛素治疗的药用组合物及方法 |
| DE102005016981A1 (de) | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| JP2009520806A (ja) | 2005-12-21 | 2009-05-28 | ファイザー・プロダクツ・インク | ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ |
| WO2007083640A1 (ja) * | 2006-01-18 | 2007-07-26 | Kyorin Pharmaceutical Co., Ltd. | 頻尿及び尿失禁の予防又は治療剤 |
| JP5451613B2 (ja) | 2007-08-06 | 2014-03-26 | アラーガン、インコーポレイテッド | デスモプレシン薬物送達のための方法及びデバイス |
| CN101648017A (zh) | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| WO2010028211A1 (en) | 2008-09-04 | 2010-03-11 | Rozmanith Anthony I | Health care |
| DK2381923T4 (da) * | 2008-12-22 | 2023-09-11 | Acerus Pharmaceuticals Usa Llc | Intranasal administration af desmopressin |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| PL3679941T3 (pl) | 2009-06-18 | 2023-04-17 | Serenity Pharmaceuticals Llc | Bezpieczne podawanie desmopresyny |
| MX2012004134A (es) * | 2009-10-07 | 2012-05-08 | Merck Sharp & Dohme | Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) * | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| CA2866853A1 (en) | 2012-03-19 | 2013-07-26 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| GB201312155D0 (en) | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
| JP2016525147A (ja) | 2013-07-23 | 2016-08-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物 |
| MX2016001030A (es) * | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| WO2015034822A1 (en) | 2013-09-03 | 2015-03-12 | G2B Pharma Inc. | Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions |
| ES2923438T3 (es) | 2014-11-20 | 2022-09-27 | Serenity Pharmaceuticals Llc | Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico |
-
2014
- 2014-07-23 MX MX2016001030A patent/MX2016001030A/es unknown
- 2014-07-23 ES ES14748451T patent/ES2910361T3/es active Active
- 2014-07-23 WO PCT/US2014/047899 patent/WO2015013454A1/en active Application Filing
- 2014-07-23 JP JP2016529872A patent/JP2016525548A/ja active Pending
- 2014-07-23 CA CA2919198A patent/CA2919198A1/en active Pending
- 2014-07-23 AU AU2014293141A patent/AU2014293141A1/en not_active Abandoned
- 2014-07-23 US US14/338,554 patent/US9814753B2/en not_active Expired - Fee Related
- 2014-07-23 KR KR1020247002750A patent/KR20240015735A/ko active Application Filing
- 2014-07-23 EP EP14748451.3A patent/EP3024474B1/en active Active
- 2014-07-23 KR KR1020217025792A patent/KR20210103589A/ko active Application Filing
- 2014-07-23 CN CN201480052301.7A patent/CN105579057A/zh active Pending
- 2014-07-23 KR KR1020167004515A patent/KR20160033220A/ko not_active Application Discontinuation
- 2014-07-23 DK DK14748451.3T patent/DK3024474T3/da active
-
2017
- 2017-11-13 US US15/811,384 patent/US10568927B2/en active Active
-
2020
- 2020-04-01 JP JP2020065913A patent/JP7219736B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10568927B2 (en) | 2020-02-25 |
| CN105579057A (zh) | 2016-05-11 |
| KR20240015735A (ko) | 2024-02-05 |
| KR20160033220A (ko) | 2016-03-25 |
| CA2919198A1 (en) | 2015-01-29 |
| EP3024474B1 (en) | 2022-01-05 |
| EP3024474A1 (en) | 2016-06-01 |
| US20150031613A1 (en) | 2015-01-29 |
| MX2016001030A (es) | 2016-10-07 |
| KR20210103589A (ko) | 2021-08-23 |
| US9814753B2 (en) | 2017-11-14 |
| US20180289769A1 (en) | 2018-10-11 |
| WO2015013454A1 (en) | 2015-01-29 |
| JP2016525548A (ja) | 2016-08-25 |
| AU2014293141A1 (en) | 2016-02-18 |
| JP7219736B2 (ja) | 2023-02-08 |
| JP2020109122A (ja) | 2020-07-16 |
| ES2910361T3 (es) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222338A1 (zh) | 細胞受體 | |
| HK1221724A1 (zh) | 細胞受體 | |
| EP2964226A4 (en) | 2-pyridyloxy-4-ESTER-orexin receptor antagonists | |
| DK2984424T3 (da) | Forbedringer i køleskabe | |
| EP3030234A4 (en) | THIAZOLE-orexin receptor Antagonist | |
| DK3024474T3 (da) | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist | |
| DK2943549T3 (da) | Synergistisk h2s-scavenger-sammensætning | |
| DK3027750T3 (da) | Biokatalytisk sammensætning | |
| DK3019894T3 (da) | In situ accelerometer-kalibrering | |
| HK1226017A1 (zh) | S1p3拮抗劑 | |
| DK3044389T3 (da) | Vinduespost-tværstykke-konstruktion | |
| GB201322430D0 (en) | T cell receptors | |
| GB201305118D0 (en) | Blends | |
| IL243730A0 (en) | Vasopressin-2 receptor agonists | |
| GB201418840D0 (en) | In german | |
| FR3007434B1 (fr) | Structure de cabanon en kit | |
| GB201312010D0 (en) | Receptor Agonists | |
| DK3082855T3 (da) | Sammensætning | |
| GB201304666D0 (en) | Dopamine receptor antagonist | |
| FR3013565B1 (fr) | Bagage a peson | |
| BR302013006435S1 (pt) | Configuração aplicada em tênis | |
| BR302013005853S1 (pt) | Configuração aplicada em tênis | |
| BR302013004794S1 (pt) | Configuração aplicada em tênis | |
| GB201304105D0 (en) | Agonist | |
| UA27822S (uk) | Банківський автомат |